Immune checkpoint inhibitors (ICIs) have been introduced in the treatment of NSCLC to block the interaction between tumor cell-expressed PD-L1 and immune checkpoints, reactivating anti-tumor immune responses (Tang et al., 2022). This evidence concerns the gene CD274 and non-small cell lung carcinoma.